Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,890,156 papers from all fields of science
Search
Sign In
Create Free Account
ACVBP protocol
Known as:
ACVBP Regimen
, Adriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone Regimen
, LNH-87
A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin's lymphoma.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Bleomycin
Cyclophosphamide
Doxorubicin
Lymphoma, Non-Hodgkin
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
High-risk DLBCL: interim PET? Not yet.
M. Hertzberg
Blood
2017
Corpus ID: 206955328
In this issue of Blood , Casasnovas et al demonstrate that among diffuse large B-cell (DLBCL) patients with age-adjusted…
Expand
2013
2013
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients
F. Lefrère
,
Dominique bastit-Barrau
,
+14 authors
C. Haioun
Transfusion
2013
Corpus ID: 37651073
BACKGROUND: The ACVBP regimen is an efficient induction regimen for poor‐risk patients with diffuse large B‐cell lymphoma (DLBCL…
Expand
2011
2011
Intensified chemotherapy for diffuse large B-cell lymphomas
J. Vose
The Lancet
2011
Corpus ID: 8169662
2009
2009
Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).
N. Mounier
,
C. Gisselbrecht
,
+8 authors
C. Haioun
Journal of Clinical Oncology
2009
Corpus ID: 36312820
8507 Background: Rituximab (R) combined with CHOP improves survival in DLBCL pts. More intensive regimen followed by auto…
Expand
2008
2008
Combination of rituximab with chemotherapy in diffuse large B‐cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication
H. Ghesquières
,
C. Ferlay
,
+7 authors
P. Biron
Hematological Oncology
2008
Corpus ID: 22160711
Randomized trials have demonstrated improved outcome from adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine…
Expand
Review
2004
Review
2004
Stem Cell Transplantation for Hematologic Malignancies
R. Soiffer
Contemporary Hematology
2004
Corpus ID: 10028996
form that compared HDT and autoSCT to either standard front-line chemotherapy or high-intensity front-line chemotherapy (49-51…
Expand
2001
2001
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.
R. Fisher
Journal of the National Cancer Institute
2001
Corpus ID: 36563115
Long-term follow-up of numerous single-institution and national cooperative group clinical trials have confirmed that at least…
Expand
2001
2001
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients.
M. André
,
N. Mounier
,
+9 authors
C. Gisselbrecht
2001
Corpus ID: 58812590
1998
1998
A multivariate analysis of the survival of patients with aggressive lymphoma
N. Mounier
,
P. Morel
,
+8 authors
É. Lepage
1998
Corpus ID: 72635950
Aggressive non‐Hodgkin's lymphoma is now often curable with chemotherapy. The International Prognostic Index (IPI) was recently…
Expand
1993
1993
[Must low-burden aggressive lymphomas be treated with intensive chemotherapy? (LNH-87, Group 1)].
H. Tilly
Pathologie et biologie
1993
Corpus ID: 43258915
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE